Most readers would already be aware that Johnson & Johnson's (NYSE:JNJ) stock increased significantly by 11% over ...

Johnson & Johnson (NYSE:JNJ – Get Free Report) was the target of some unusual options trading on Thursday. Stock traders purchased 58,414 call options on the stock. This is an increase of ...

The final trades of the day with the Fast Money traders. Los Angeles removes fire chief in wake of massive wildfires Shilo Sanders not invited to Combine, but hires official Combine timers to verify ...

US healthcare giant Johnson & Johnson has announced data from the Phase III ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

(formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate ...

Sanctuary Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 10.4% during the fourth quarter, ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Johnson & Johnson will resume the limited market release of VARIPULSE in the United States after a comprehensive ...